Global Cell and Gene Therapy Clinical Trial Market 2023-2029

Global Cell and Gene Therapy Clinical Trial Market 2023-2029

Cell therapy aims to treat diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body. With cell therapy, cells are cultivated or modified outside the body before being injected into the patient. Gene therapy aims to treat diseases by replacing, inactivating or introducing genes into cells - either inside the body (in vivo) or outside of the body (ex vivo). The global cell and gene therapy clinical trial market is likely to register a CAGR of over 12.3% with an incremental growth of USD 7.2 billion during the forecast period 2023-2029.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global cell and gene therapy clinical trial market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the phase, indication, and region. The global market for cell and gene therapy clinical trial can be segmented by phase: phase I, phase II, phase III, phase IV. The phase II segment was the largest contributor to the global cell and gene therapy clinical trial market in 2022. Cell and gene therapy clinical trial market is further segmented by indication: cardiology, CNS diseases, endocrine, metabolic and genetic, gastroenterology, hematology, immunology and inflammation, musculoskeletal, oncology, ophthalmology, others. According to the research, the oncology segment had the largest share in the global cell and gene therapy clinical trial market. Based on region, the cell and gene therapy clinical trial market is segmented into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America held the largest revenue share in 2022.

Market Segmentation

By phase: phase I, phase II, phase III, phase IV

By indication: cardiology, CNS diseases, endocrine, metabolic and genetic, gastroenterology, hematology, immunology and inflammation, musculoskeletal, oncology, ophthalmology, others

By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report also provides analysis of the key companies of the industry and their detailed company profiles including Charles River Laboratories International, Inc., ICON plc, IQVIA Holdings Inc., Laboratory Corporation of America Holdings (Labcorp), Medpace Holdings, Inc., Novotech Health Holdings Ltd., PAREXEL International Corporation, PPD, Inc., PSI CRO AG, Syneos Health, Inc., Veristat, LLC, WuXi AppTec, Inc., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report

• To analyze and forecast the market size of the global cell and gene therapy clinical trial market.
• To classify and forecast the global cell and gene therapy clinical trial market based on phase, indication, region.
• To identify drivers and challenges for the global cell and gene therapy clinical trial market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global cell and gene therapy clinical trial market.
• To identify and analyze the profile of leading players operating in the global cell and gene therapy clinical trial market.

• Gain a reliable outlook of the global cell and gene therapy clinical trial market forecasts from 2023 to 2029 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.